Endo International PLC (NASDAQ: ENDP) Qwo® Statistics to Be Accessible at Beautifying Boot camp 2021

Endo International PLC (NASDAQ: ENDP) announced today that statistics from readings of Endo Aesthetics’ Qwo®, which obtained FDA endorsement in July 2020 for the cure of reasonable to stark cellulite in the backsides of adult women, will be accessible during Cosmetic Bootcamp Summer Event.

Data to be presented at the conference

The company will underscore the statistics in three e-posters obtained during the computer-generated and in-person conference in Aspen, CO, June 24–27, 2021.

Novel statistics: Valuation of Extenuation Cures on Injection-Site Staining of Collagenase Clostridium se Histolyticum-aaes cure of Buttock Cellulite in Women: A Phase 4, Open-Label Trial

Real-World Efficiency and Security of Collagenase Clostridium Histolyticum-aaes Inoculations for the Cure of Thigh Cellulite in Women: An Intervening Examination

Effect of Body Mass Index and Stage on Answer to Collagenase Clostridium Histolyticum-aaes Cure of Buttock Cellulite: A Joint Examination of Two Phase 3 Randomized, Placebo-Controlled Trials

Vital Security Information For QWO Contraindications

 QWO is contraindicated in patients with a past of hypersensitivity to collagenase or any of the excipients or the attendance of contagion at the injection sites.

Considerate hypersensitivity responses counting anaphylaxis have been stated with the use of collagenase clostridium histolyticum. If such a response happens, further inoculation of QWO should be superseded and appropriate medical treatment directly introduced. Counsel patients to seek direct medical attention if they knowledge any indications of severe hypersensitivity responses.

In scientific trials, 84% of themes treated with QWO suffered inoculation site staining. QWO should be used carefully in patients with hemorrhage irregularities or who are presently being treated with antiplatelet or anticoagulant therapy. QWO must not be replaced with other injectable collagenase products. QWO is not envisioned for the cure of Peyronie’s Disease or Dupuytren’s Contracture.

In scientific trials, the most usually reported opposing responses in patients cured with QWO occurrence ≥ 10% were at the inoculation site: staining, discomfort, nodule, and pruritus.

Leave a Comment

Your email address will not be published.